Preclinical data suggest that pharmacological inhibition of ADAM17 reduces pulmonary inflammation, diminishes leukocyte infiltration, and improves the neutrophil-to-lymphocyte ratio—an established marker of COVID-19 severity (Haga et al., 2008; Zipeto et al., 2020). This evidence concerns the gene ADAM17 and COVID-19.